Preventing pre-eclampsia with low-dose aspirin in women after frozen embryo transfer
Official title: A Prospective Interventional Randomized Controlled Trial to Assess the Effect of Low Dose Acetylsalicylic Acid As a Preventive Treatment of Pre-eclampsia in Pregnant Women Who Underwent Frozen Embryo Transfer
Run by Centre Hospitalier Universitaire de Liege · NCT05460416 · Data updated 2026-11-12
This study is testing if taking low-dose aspirin can help prevent pre-eclampsia in pregnant women who have had a frozen embryo transfer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 43 Years |
| Sex | Women only |
| Enrollment | 276 (estimated) |
| Sponsor | Centre Hospitalier Universitaire de Liege Academic / other |
| Locations | 1 site (Liège) |
| Status | Recruiting |
| Started | October 25, 2022 |
| Main results expected | December 31, 2025 |
| Study ends | June 30, 2026 |
| Registry record updated | February 18, 2025 |
| Trial ID | NCT05460416 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are healthy women aged 18 to 43 who are planning a frozen embryo transfer and have a confirmed pregnancy at six weeks.
✕Probably not a fit
Patients with risk factors for pre-eclampsia or contraindications to acetylsalicylic acid will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a prospective, multicentric, interventional randomized controlled trial aimed at evaluating the effectiveness of low-dose acetylsalicylic acid as a preventive treatment for pre-eclampsia in pregnant women who have undergone frozen embryo transfer. Participants will be randomly assigned to receive either the treatment or no treatment after confirming an intrauterine pregnancy at six weeks. The primary goal is to assess the incidence of pre-eclampsia in both groups, with regular follow-ups to monitor health outcomes throughout the pregnancy. The study will include women aged 18 to 43 who meet specific eligibility criteria and have provided informed consent.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the incidence of pre-eclampsia in women undergoing frozen embryo transfer.
How similar studies have gone: Other studies have shown promising results with low-dose aspirin in preventing pre-eclampsia, suggesting this approach may be effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy women from \[18 - 43\] years-old, planned for a frozen embryo transfer, with natural and modified natural or HRT cycle * Who have given their informed consent * Who have a confirmed pregnancy at week 6 of amenorrhea. Exclusion Criteria: * Women presenting one risk factor for preeclampsia: multiple pregnancy, history of preeclampsia, BMI \> 30, lupus syndrome, preexistent proteinuria, non-treated chronic high blood pressure (\>140/90), antiphospholipid antibody syndrome, diabetes (fasting blood sugar \>126mg/dl) * Contraindication to acetylsalicylic acid (at risk of active hemorrhage (like hemophilia, …); at risk of or who have a gastro-duodenal ulcer; at risk or how have a terminal renal or hepatic in-sufficiency (only if acetylsalicylic acid is given at high dose) * Already treated with acetylsalicylic acid * Treatment with anticoagulants or non-steroid anti-inflammatory drugs
Where it's running
-
Centre Hospitalier Universitaire de Liège site Citadelle
Liège, Belgium Recruiting
Study contacts
- Principal investigator: Laurie Henry — Centre Hospitalier Régional de la Citadelle
- Study coordinator: Julie Collée
- Email: julie.collee@uliege.be
- Phone: +32498973386
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Preeclampsia Biomarker Test in African Women
This study tests whether measuring the sFlt-1/PlGF ratio using quick clinic tests helps predict which pregnant women in Africa will develop severe preeclampsia.
-
Pentoxifylline to improve uterine lining and frozen embryo transfer outcomes
This trial sees if giving pentoxifylline alongside standard estradiol helps women with good-quality day‑5 frozen embryos get a thicker uterine lining and better frozen embryo transfer success.
-
Aspirin with or without low‑molecular‑weight heparin to prevent preeclampsia in high‑risk pregnancy
This trial tests whether adding low‑molecular‑weight heparin (tinzaparin) to low‑dose aspirin reduces the chance of preeclampsia in pregnant people identified as high risk in the first trimester.
-
Two phone-based approaches to manage high blood pressure after delivery
This trial tests whether two different mobile phone programs help people with pregnancy-related high blood pressure after delivery control their blood pressure, protect heart function, and feel more involved in their care.
-
Triggering ovulation at smaller versus larger follicle sizes in a modified natural cycle
This trial tests whether triggering ovulation when follicles are 13–16.9 mm works as well as triggering at 17–22 mm for people having a modified natural cycle frozen embryo transfer.
-
Effects of Corpus Luteum on Frozen Embryo Transfer Pregnancies
This study is testing how the corpus luteum affects pregnancies from frozen embryo transfers to see if it influences things like heart health and fetal growth.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.